June 24 (Reuters) - AstraZeneca ( AZN ) said on Tuesday
that U.S. regulators have approved its precision drug Datroway
to treat a type of lung cancer, adding that the drugmaker would
now pay partner Daiichi Sankyo ( DSKYF ) $45 million in
milestone-related considerations.
(Reporting by Pushkala Aripaka in Bengaluru)